Keeping in view that an analog of AcSDKP that is resistant to ACE degradation has shown similar functions compared with AcSDKP (Ma et al., 2014), we suggest that both AcSDKP and its analogs have a promising perspective in the treatment of IBD, as well as other inflammatory diseases. This evidence concerns the gene TMSB4X and inflammatory bowel disease.